tepadina 15 mg
mbi pharma ltd., israel - thiotepa - powder for concentrate for solution for infusion - thiotepa 15 mg/vial - thiotepa - tepadina is indicated, in combination with other chemotherapy medicinal products:1. with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;2. when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients.
thiotepa riemser
esteve pharmaceuticals gmbh - thiotepa - hematopoietic stem cell transplantation; neoplasms - antineoplastic agents - thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients.thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients
thiotepa riemser 100 mg
a.l. medi-market ltd. - thiotepa - powder for concentrate for solution for infusion - thiotepa 100 mg/vial - thiotepa - thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:1. with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;2. when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients.
thiotepa riemser 15 mg
a.l. medi-market ltd. - thiotepa - powder for concentrate for solution for infusion - thiotepa 15 mg/vial - thiotepa - thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:1. with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;2. when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients.
thiotepa medomie 100 mg
medomie pharma ltd, israel - thiotepa - powder for concentrate for solution for infusion - thiotepa 100 mg/vial - thiotepa - indicated in combination with other chemotherapy medicinal products:1. with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients.2. when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients.
thiotepa medomie 15 mg
medomie pharma ltd, israel - thiotepa - powder for concentrate for solution for infusion - thiotepa 15 mg/vial - thiotepa - indicated in combination with other chemotherapy medicinal products:1. with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients.2. when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients.
thiotepa-reach thiotepa 100 mg powder for injection vial
reach pharmaceuticals pty ltd - thiotepa, quantity: 100 mg - injection, powder for - excipient ingredients: - thiotepa-reach is indicated, in combination with other chemotherapy medicinal products: ? with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients; ? when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients. (refer to section 5.2 clinical trials)
thiotepa-reach thiotepa 15 mg powder for injection vial
reach pharmaceuticals pty ltd - thiotepa, quantity: 15 mg - injection, powder for - excipient ingredients: - thiotepa-reach is indicated, in combination with other chemotherapy medicinal products: ? with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients; ? when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients. (refer to section 5.2 clinical trials)
tepadina powder for concentrate for solution for infusion 100mgvial
axxessbio pte. ltd. - thiotepa - injection, powder, lyophilized, for solution - thiotepa 100mg/vial
tepadina powder for concentrate for solution for infusion 15mgvial
axxessbio pte. ltd. - thiotepa - injection, powder, lyophilized, for solution - thiotepa 15mg/vial